9,260 Shares in Evolent Health, Inc. (NYSE:EVH) Bought by Cassaday & Co Wealth Management LLC

Cassaday & Co Wealth Management LLC purchased a new stake in shares of Evolent Health, Inc. (NYSE:EVH) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 9,260 shares of the technology company’s stock, valued at approximately $262,000.

Other institutional investors have also recently bought and sold shares of the company. Covestor Ltd grew its holdings in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after acquiring an additional 1,556 shares in the last quarter. Quarry LP acquired a new position in Evolent Health during the 2nd quarter valued at about $32,000. Canada Pension Plan Investment Board bought a new stake in Evolent Health during the 2nd quarter worth approximately $61,000. Finally, Quest Partners LLC purchased a new stake in shares of Evolent Health in the second quarter worth approximately $87,000.

Insider Buying and Selling

In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $5,637,120.00. Following the sale, the chief executive officer now directly owns 411,924 shares in the company, valued at $12,357,720. The trade was a 31.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Emily Ann Rafferty sold 8,861 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the transaction, the chief operating officer now directly owns 63,408 shares in the company, valued at $1,902,240. This represents a 12.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 307,291 shares of company stock valued at $9,290,385. 1.60% of the stock is owned by company insiders.

Evolent Health Stock Down 0.3 %

EVH opened at $12.35 on Tuesday. Evolent Health, Inc. has a twelve month low of $12.18 and a twelve month high of $35.00. The company’s 50-day moving average price is $24.75 and its two-hundred day moving average price is $24.19. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -13.57 and a beta of 1.58. The company has a quick ratio of 1.08, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Analyst Ratings Changes

EVH has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a research report on Tuesday, November 12th. Truist Financial reaffirmed a “buy” rating and set a $33.00 price objective on shares of Evolent Health in a report on Tuesday, August 27th. Barclays lowered their target price on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, November 11th. KeyCorp began coverage on shares of Evolent Health in a report on Friday, October 11th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $28.90.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.